Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
94982 trials found · Page 147 of 4750
-
New stem cell transplant method aims to reduce side effects for blood cancer patients
Disease control Recruiting nowThis is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophyl…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New targeted radiation shows promise for Drug-Resistant lung cancer
Disease control Not yet recruitingNon-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and accounts for approximately 80% of all lung cancer cases. Despite advances in chemotherapy, radiotherapy, and immunotherapy, the prognosis of patients with advanced-stage metastatic N…
Phase: PHASE2 • Sponsor: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Promising combo targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThe purpose of this prospective, multicenter, Phase 2 study is to evaluate the efficacy and safety of Mosunetuzumab in combination with the EZH2 inhibitor Zeprumetostat (SHR2554) in patients with follicular lymphoma (FL). The study plans to enroll approximately 80 patients, who w…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New lupus drug shows promise in major trial
Disease control Recruiting nowThis study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 03:50 UTC
-
Hope for Huntington's: new pill targets harmful proteins in Long-Term study
Disease control ENROLLING_BY_INVITATIONThe goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genet…
Phase: PHASE2, PHASE3 • Sponsor: Skyhawk Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for lung cancer patients with brain tumors: drug combo trial launches
Disease control Recruiting nowThe researchers are doing this study to test the safety of ivonescimab given in combination with standard chemotherapy and stereotactic radiosurgery (SRS) in people with non-small cell lung cancer (NSCLC) that has spread to the brain (brain metastases). The researchers will test …
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC
-
New hope for liver cancer patients who have run out of options
Disease control Not yet recruitingThis is a randomized, open-label, multicenter Phase Ib/II registration trial designed to evaluate the efficacy and safety of HH-009 in patients with FGF19-positive hepatocellular carcinoma (HCC). The study will also assess pharmacokinetics, pharmacodynamics, immunogenicity, and e…
Phase: PHASE1, PHASE2 • Sponsor: Huahui Health • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New dengue drug shows promise in clinical trial
Disease control Recruiting nowThis is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
Phase: PHASE2, PHASE3 • Sponsor: Hyundai Bioscience Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for tough lung cancer: drug duo takes on chemo
Disease control Not yet recruitingThis is a randomized, open-label, multi-center, global phase II/III clinical study to evaluate the efficacy and safety of HLX43 monotherapy or HLX43 in combination with HLX07 vs. docetaxel in the treatment of advanced squamous NSCLC after failure of first-line treatment.
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug combo aims to extend life in advanced kidney cancer
Disease control Recruiting nowResearchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New combo therapy aims to outsmart drug-resistant lung cancer
Disease control Recruiting nowThe researchers are doing this study to find out whether ivonescimab in combination with datopotamab deruxtecan- (Dato-DXd) or osimertinib are safe and effective treatments in people with non-small cell lung cancer (NSCLC) that has an EGFR mutation. The researchers will test diff…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New antibody therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug duo aims to supercharge immune attack on head and neck tumors before surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn if drug CADI-05, when used together with pembrolizumab (an FDA approved immunotherapy), can help treat locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in adults. It will also learn about the safety of drug CADI-05. The…
Phase: PHASE1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Mobile clinics and peer support aim to curb opioid crisis in rural communities
Disease control Recruiting nowThis study will provide longitudinal data for 6-months on a target sample of patients with Opioid Use Disorder (OUD) recruited from Prisma Health Mobile Health Clinics in South Carolina. The goal of our study is to increase OUD treatment initiation and retention and maximize prev…
Phase: NA • Sponsor: Prisma Health-Upstate • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Experimental protein therapy aims to shrink HIV-Linked cancers by reviving immune cells
Disease control Recruiting nowBackground: Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. KS is caused by a virus known as Kaposi sarcoma herpesvirus. People infected with human immunodeficiency virus (HIV) account for 80% of KS cases in the Uni…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 03:48 UTC
-
New combo therapy aims to control prostate cancer
Disease control Recruiting nowThe study aims to assess the safety and tolerability of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer, and determine the recommended Phase II dose (RP2D); To evaluate of the efficacy of SHR-4394 in combination with anti-tumor therapy in part…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New hope for AFib patients: second ablation with advanced catheter under study
Disease control Recruiting nowConquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillat…
Phase: NA • Sponsor: Medtronic Cardiac Ablation Solutions • Aim: Disease control
Last updated May 16, 2026 03:49 UTC
-
New drug aims to delay relapse in High-Risk blood cancer
Disease control Not yet recruitingThe purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 04, 2026 16:24 UTC
-
Could freezing breast cancer replace the knife?
Disease control Recruiting nowLUBRECA will evaluate the safety and efficacy of cryoablation with liquid nitrogen to treat cT1cN0 luminal breast cancer diagnosed in postmenopausal women
Phase: NA • Sponsor: Lucía Graña López • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Blood tests could guide lung cancer treatment choices
Knowledge-focused Recruiting nowThis phase II trial tests the impact of biomarkers in predicting initial treatment (first-line) PD1 or PD-L1 (PD\[L\]-1)-based immunotherapy response and in selecting second-line treatment in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Response and survival ra…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated May 11, 2026 20:39 UTC